News

IPA announces optimization results of TATX-03 cocktail components designed to improve clinical suitability of their PolyTope therapy

TATX-21, a novel potential first-in-class antibody for Atherosclerosis Cardiovascular Disease (ACVD).

Since 2019, Dr. Ilse Roodink has served as Chairwoman of Talem Therapeutics’ Scientific Advisory Committee and has been instrumental in leading IPA’s SARS-CoV-2 Polytope™ Cocktail program

Dr. Neame will play a key role in supporting the strategic and scientific prioritization of partnerships and stakeholder communications.

Demonstrating what the Company believes to be the first reported in vivo synergistic effects of a multi-antibody (3+) combination treatment

LifeSci Advisors provides life science companies comprehensive solutions to communications and investor outreach.